Who makes Ketotifen 4.0% Patch?

Ketotifen 4.0% Patch is developed by Senju USA, Inc..

What development phase is Ketotifen 4.0% Patch in?

Ketotifen 4.0% Patch is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Ketotifen 4.0% Patch

Senju USA, Inc. · Phase 2 active Small molecule

At a glance

Generic name	Ketotifen 4.0% Patch
Sponsor	Senju USA, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ketotifen 4.0% Patch CI brief — competitive landscape report
Ketotifen 4.0% Patch updates RSS · CI watch RSS
Senju USA, Inc. portfolio CI